deltatrials
Completed PHASE1 NCT01952782

Neuropeptides in Human Reproduction

Sponsor: Massachusetts General Hospital

Conditions Hypogonadotropic Hypogonadism
Interventions GnRH Kisspeptin 112-121 Naloxone
Updated 15 times since 2017 Last updated: Jul 30, 2024 Started: Apr 30, 2014 Primary completion: May 31, 2016 Completion: May 31, 2016

A PHASE1 clinical study on Hypogonadotropic Hypogonadism, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 15 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

  4. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Sep 2022 — Aug 2023 [monthly]

    Recruiting PHASE1

▶ Show 10 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  3. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  4. Jan 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  5. Jul 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  6. Jan 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  7. Jul 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  9. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States